Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis

Sutherland, Lloyd R.; MacDonald, JK

doi:10.1002/14651858.cd000543

Cited by 100 publications

(107 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immediately after burn or sham injury, mice were given an intraperitoneal injection of either 1 mL of normal saline as described above or 100mg/kg of 5-ASA dissolved in 1 mL of saline used for the normal resuscitation. The dose for 5-ASA was selected from a previous study, and it most closely mimics the dosage used to treat IBD patients 29, 30 …”

Section: Methodsmentioning

confidence: 99%

Effects of Mesalamine Treatment on Gut Barrier Integrity After Burn Injury

Cannon

Akhtar

Hammer

et al. 2016

Journal of Burn Care & Research

View full text Add to dashboard Cite

Gut barrier disruption is often implicated in pathogenesis associated with burn and other traumatic injuries. In this study, we examined whether therapeutic intervention with mesalamine (5-ASA), a common anti-inflammatory treatment for patients with inflammatory bowel disease, reduces intestinal inflammation and maintains normal barrier integrity after burn injury. Male C57BL/6 mice were administered an ~20% total body surface area dorsal scald burn and resuscitated with either 1mL normal saline or 100mg/kg of 5-ASA dissolved in saline. We examined intestinal transit and permeability along with levels of small intestine epithelial cell pro-inflammatory cytokines and tight junction protein expression one day after burn injury in the presence or absence of 5-ASA. A significant decrease in intestinal transit was observed one day after burn injury, which accompanied a significant increase in gut permeability. We found a substantial increase in the levels of IL-6 (by ~1.5 fold) and IL-18 (by ~2.5 fold) in small intestine epithelial cells one day after injury. Furthermore, burn injury decreases expression of the tight junction proteins claudin-4, claudin-8, and occludin. Treatment with 5-ASA after burn injury prevented the burn induced increase in permeability, partially restored normal intestinal transit, normalized levels of the pro-inflammatory cytokines IL-6 and IL-18, and restored tight junction protein expression of claudin-4 and occludin to that of sham levels. Together these findings suggest that 5-ASA can potentially be used as treatment to decrease intestinal inflammation and normalize intestinal function after burn injury.

show abstract

Section: Methodsmentioning

confidence: 99%

Effects of Mesalamine Treatment on Gut Barrier Integrity After Burn Injury

Cannon

Akhtar

Hammer

et al. 2016

Journal of Burn Care & Research

View full text Add to dashboard Cite

show abstract

“…4.8 g) 5-ASA for induction of remission in mild-to-moderate UC. 19,20 Moreover, there are several 5-ASA delivery systems available. Respondents endorsing the use of 5-ASA in vignette #2 were asked to select among the following: balsalazide 6.75g, mesalamine 2.4g, mesalamine 4.8g, micronized mesalamine 4g, delayed-release ( i.e.…”

Section: Methodsmentioning

confidence: 99%

“…19,20 Similarly, it is uncertain whether long-term 5-ASA has important benefits for cancer chemoprevention. 19,21,22 We asked the following question: “In a patient with UC in remission on 6MP/AZA, do you continue 5-ASA products?” Respondents were instructed to select all that apply among the following choices: (a) “No, I taper them off to reduce pill burden;” (b) “No, I taper them off because it is not incrementally effective;” (c) “Yes, for purposes of treatment of disease;” and (d) “Yes, for purposes of cancer chemoprevention.” We compared responses between groups using chi-squared tests.…”

Section: Methodsmentioning

confidence: 99%

Controversies in Ulcerative Colitis: A Survey Comparing Decision Making of Experts Versus Community Gastroenterologists

Spiegel

Esrailian

et al. 2009

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

Background Despite the development of consensus guidelines in ulcerative colitis (UC), there remain several areas of uncertainty in the everyday management of this incompletely understood disease. We performed a national vignette survey to measure variations in decision-making in areas of controversy. Methods We constructed a survey with 3 vignettes to measure decision-making in 4 areas of controversy in UC: (1) dysplasia management, (2) 5-ASA dosing, (3) diagnostic testing for underlying Crohn’s Disease, and (4) treatment of steroid-refractory inpatient UC. We compared responses between a group of community gastroenterologists and UC experts. Results We received 192 responses (36% response). Compared to community gastroenterologists, UC experts were more likely to endorse colectomy for both unifocal and multifocal low grade dysplasia, use narrow band imaging and chromoendoscopy for surveillance colonoscopy, use high-dose 5-ASA for inducing remission, use long-term 5-ASA for cancer chemoprevention, order CT enterography to evaluate for Crohn’s disease, and to have a lower threshold to call for surgery consultation in steroid-refractory UC. There was little agreement regarding the optimal frequency of surveillance colonoscopy, even among experts. Most respondents favored using infliximab over cyclosporin in steroid-refractory UC. Conclusions Community gastroenterologists and UC experts vary dramatically in their approach to many areas of uncertainty in UC. The only area of consensus between groups is the use of infliximab over CSA in steroid-refractory UC – itself a controversial decision. These data suggest that current practice patterns are highly disparate, and focus attention on specific areas of disconnect that should be further investigated.

show abstract

“…Oral 5-ASA compounds, including olsalazine, sulfasalazine mesalamine, balsalazide are effective in inducing remissions in active ulcerative colitis although side effects are significantly higher with sulfasalazine [17, 18]. Sulfasalazine is effective for the treatment of Crohn's colitis, but is less useful in patients with active ileitis.…”

Section: Medical Therapymentioning

confidence: 99%

Common Pitfalls in Management of Inflammatory Bowel Disease

2009

View full text Add to dashboard Cite

Our understanding of inflammatory bowel disease (IBD), treatment options, complications and their management has expanded significantly over the past few decades. When caring for patients it is important to remember the complexities of pathogenesis and pharmacology. This review is to identify errors in diagnosis, treatment, complications and preventive care issues that arise while caring for patients with IBD and to provide recommendations and information that can be shared with patients and their health care providers. A review of the literature was undertaken using MEDLINE from 1981 to present. We included randomized controlled studies, case-control studies, and review articles. There are many associated conditions and complications recognized in patients with IBD and current treatment strategies do result in many side effects, some are serious and some are not widely recognized. With the advent of anti-TNF therapies and the newer 5-amino salicylate derivatives, options available have increased significantly. It is also important to remember that these patients are followed by more than one health care provider and it is important for all involved to communicate the plan of action.

show abstract

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis

Cited by 100 publications

References 49 publications

Effects of Mesalamine Treatment on Gut Barrier Integrity After Burn Injury

Effects of Mesalamine Treatment on Gut Barrier Integrity After Burn Injury

Controversies in Ulcerative Colitis: A Survey Comparing Decision Making of Experts Versus Community Gastroenterologists

Common Pitfalls in Management of Inflammatory Bowel Disease

Contact Info

Product

Resources

About